CTIS2023-504484-16-00
Recruiting
Phase 1
CO43923 Master Protocol: A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients with Multiple Myeloma CO43923 Substudy 1: A Non-Interventional Study to Collect Patient-Level Data in Patients with Multiple Myeloma CO43923 Substudy 2 Cevos + Len Treatment: A Phase Ib, Single Arm, Open-Label Study Evaluating the Safety and Efficacy of Cevostamab in Combination with Lenalidomide in Patients with Cytogenetic High-Risk Features Receiving Maintenance Treatment After First Response from Multiple Myeloma Post-Stem Cell Transplant CO43923 Substudy 4 Cevostamab+ Iberdomide Treatment: A Phase Ib, Single Arm, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Combination with Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma - CO43923
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Multiple Myeloma (MM)
- Sponsor
- F. Hoffmann-La Roche AG
- Enrollment
- 170
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •CO43923 Master Protocol: Diagnosed with multiple myeloma (MM) per International Myeloma Working Group (IMWG) criteria, CO43923 Master Protocol: Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2, CO43923 Substudy 1: A current or past diagnosis of MM in the first line or later setting, including maintenance therapy, CO43923 Substudy 2 Cevos \+ Len Treatment: Completion of planned induction therapy and achievement of at least a partial response (PR), CO43923 Substudy 4 Cevostamab\+ Iberdomide Treatment: Previously exposed to at least a PI, an IMiD, and an anti\-CD38 antibody for the treatment of R/R MM for whom no suitable SOC therapy options are available
Exclusion Criteria
- •CO43923 Master Protocol: History of other malignancy within 2 years prior to screening, except those with negligible risk of metastasis or death, CO43923 Master Protocol: History of confirmed progressive multifocal leukoencephalopathy, CO43923 Master Protocol: Known history of HIV seropositivity, CO43923 Substudy 2 Cevos \+ Len Treatment: Hypersensitivity reactions to lenalidomide or other immunomodulatory drugs, CO43923 Substudy 4 Cevostamab\+ Iberdomide Treatment: Treatment with systemic immunosuppressive medications including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti\-TNF agents within 2 weeks prior to starting pre\-phase
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Evaluation of immunological persistence following 3-dose priming with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine in study 111654 and safety and immunogenicity following a booster dose of the same vaccine.Healthy volunteers (a single-dose booster vaccination against Streptococcus pneumoniae, diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases in healthy children 18 to 21 months of age, who were previously primed with three doses of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine, co-administered with HRV and DTPa-combined vaccines)MedDRA version: 18.0Level: LLTClassification code 10042197Term: Streptococcus pneumoniae septicaemiaSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10042195Term: Streptococcus pneumoniae pneumoniaSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10054642Term: Streptococcus pneumoniae septicemiaSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10035648Term: Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia]System Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2012-000819-82-Outside-EU/EEAGlaxoSmithKline Biologicals238
Not yet recruiting
Not Applicable
A multi center, phase 3 study to evaluate safety and efficacy of extensive intraoperative peritoneal lavage, that project to prevent recurrence, in the laparoscopic surgery for advanced colon cancerJPRN-UMIN000048457Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group2,600
Completed
Not Applicable
A youth culturally adapted manual assisted psychological therapy for adolescent Pakistani patients with a recent history of self-harmSelf harmMental and Behavioural DisordersISRCTN57325925Pakistan Institute of Learning and Living684
Completed
Not Applicable
Collecting COMPACT data for CRPS clinical studies 1.0ISRCTN33817530Royal United Hospitals Bath NHS Foundation Trust98
Completed
Not Applicable
Pilot study for the evaluation of a combined psycho- and physiotherapeutic treatment program for patients with chronic pelvic pain syndrome (CPPS)ISRCTN43221600niversity Medical Center Hamburg60